发明名称 |
Inhibitors of the activity of complex (III) of the mitochondrial electron transport chain and use thereof |
摘要 |
The present invention relates to inhibitors of the activity of Complex (III) of the mitochondrial electron transport chain and use thereof in treatment and/or prevention of cancers presenting tumor-initiating cells. The present invention further relates to pharmaceutical compositions containing said inhibitors alone or in combination with other pharmaceutically active agents, and their use as medicaments or as agrochemicals where their properties as inhibitors of the mitochondrial respiration is of benefit. |
申请公布号 |
US9458174(B2) |
申请公布日期 |
2016.10.04 |
申请号 |
US201314401685 |
申请日期 |
2013.05.23 |
申请人 |
Stemergie Biotechnology SA |
发明人 |
Clement-Schatlo Virginie;Fessard Thomas;Barbaras Damien;Matos Joana;Carreira Erick |
分类号 |
A61K31/41;C07D495/10;C07D213/81;C07D215/28;C07C275/42;C07C39/30;C07D231/56;C07C311/08;C07D235/26;C07D405/12;C07C215/50;C07D249/06;C07C233/25;C07D263/32;C07D263/34;C07D487/10;C07C237/38;C07C237/42;C07C251/48;C07D209/42;C07D305/06;C07C49/825;C07D403/12;C07D223/28;C07D235/18;C07C233/33;C07D261/08;C07C235/60;C07C235/62;C07D263/57;C07D491/107;C07C237/40;C07C237/44;C07D277/56;C07D513/10;C07D305/08;A01N31/08;A01N33/10;A01N35/04;A01N37/24;A01N37/40;A01N37/44;A01N37/46;A01N37/50;A01N43/20;A01N43/38;A01N43/40;A01N43/42;A01N43/46;A01N43/52;A01N43/56;A01N43/60;A01N43/647;A01N43/76;A01N43/78;A01N43/80;A01N43/90;A01N47/30;C07C39/24;C07C43/178;C07C49/245;A61K31/137;A61K31/167;A61K31/17;A61K31/18;A61K31/397;A61K31/421;A61K31/44;A61K31/47;A61K31/55;A61K45/06;C07D223/24 |
主分类号 |
A61K31/41 |
代理机构 |
Harness, Dickey and Pierce, P.L.C. |
代理人 |
Harness, Dickey and Pierce, P.L.C. |
主权项 |
1. A compound selected from the group consisting of:
(a) 3-formamido-N-(heptadecan-9-yl)-2-hydroxybenzamide; (b) N-cyclopentadecyl-7-hydroxy-1H-indazole-6-carboxamide; (c) N-cyclopentadecyl-3-formamido-2-hydroxybenzamide; (d) N-cyclododecyl-3-formamido-2-hydroxybenzamide; (e) 3, 5-dichloro-N-cyclopentadecyl-2-hydroxybenzamide; (f) 3, 5-dichloro-N-decyl-2-hydroxybenzamide; (g) N-(3, 5-dichloro-2-hydroxyphenyl)undecanamide; (h) N-(4-(cyclopentadecylcarbamoyl)phenyl)-3-formamido-2-hydroxybenzamide; (i) N-(heptadecan-9-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-4-carboxamide; (j) N-(3-(1-(heptadecan-9-yl)-1H-1,2,3-triazol-4-yl)-2-hydroxyphenyl)formamide; (k) N-(3-(1-cyclopentadecyl-1H-1,2,3-triazol-4-yl)-2-hydroxyphenyl)formamide; (l) N-cyclononyl-7-hydroxy-1H-indazole-6-carboxamide; (m) N-cyclononyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-4-carboxamide; and (n) N-cyclopentadecyl-2-oxo-2, 3-dihydro-1H-benzo[d]imidazole-4-carboxamide, or a pharmaceutically acceptable salt or solvate of any one of (a)-(n). |
地址 |
Geneva CH |